

BIONTECH SE SP.ADRS

ISIN: US09075V1026 WKN: 09075V102 Asset Class: **Stock**

Company

2024/08/16 22:00:00

BIONTECH

Price

85.19

USD

Difference

-2.36% (-2.06)



Contact Details

BIONTECH SE Tel: +49-6131-9084-0
-- Fax: +
An der Goldgrube 12 Web: <http://www.biontech.de>
55131 Mainz E-mail: -

Company Profile

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	21,570,831,000		23,396,254,000		17,085,065,000	
Common stock capital		274,615,000		265,318,000		280,092,000
Fixed assets	3,843,077,000		1,448,364,000		917,720,000	
Equity capital of a company		22,364,633,000		21,404,339,000		13,525,515,000
Cash and cash equivalents	12,884,306,000		14,808,200,000		1,924,938,000	
Accrued liabilities		9,720,000		9,178,000		210,268,000
Other assets	-		-		-	
Current liabilities		2,287,177,000		3,149,027,000		3,959,275,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		762,098,000		291,252,000		517,994,000
Different income		-		-		-
Other liabilities		497,534,000		87,407,000		36,731,000
Total assets	25,413,909,000	25,413,909,000	24,844,619,000	24,844,619,000	18,002,785,000	18,002,785,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	3,082	4,530	3,082
Equity ratio	88.00%	86.15%	75.13%
Debt-equity ratio	13.63%	16.07%	33.10%

Others

	2023	2022	2021
Tax Expense Rate	21.57%	27.17%	31.59%

BIONTECH SE SP.ADRS

ISIN: US09075V1026

WKN: 09075V102

Asset Class: **Stock**

Income statement

	2023	2022	2021
Turnover	4,128,780,000	18,192,996,000	22,430,097,000
Net income	1,005,761,000	9,915,312,000	12,165,538,000
EBIT	821,235,391	12,333,791,867	16,156,121,896
Operating income before taxes	1,282,311,000	13,614,426,000	17,784,557,000
Cash Flow	5,807,104,000	14,269,498,000	1,051,608,000
Net interest income	378,066,000	33,946,000	-4,609,000
Research and development expenses	1,927,737,000	1,563,534,000	1,083,049,000
Income taxes	276,549,000	3,699,114,000	5,619,019,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,216,664	3,647,435	6,609,674

Board of Directors

Members of Management Board